A plane carrying more than 40 000 doses of AstraZeneca COVID-19 vaccine and 40 000 antigen-based rapid diagnostic tests donated by Malta has just arrived at Mitiga international airport in Tripoli.
The Central Procurement and Supplies Unit within the Maltese Ministry of Health managed the delivery of these essential supplies to Libya, in coordination with the European Union, the World Health Organization (WHO) and the Libyan Ministry of Health.
“Today’s donation of COVID-19 vaccines and antigen-based rapid diagnostic test kits confirms the support of Malta towards Libya and its people. It is our hope that this donation will contribute to strengthening national efforts to overcome the COVID-19 pandemic,” said H.E. Mr Charles Saliba, the Ambassador of Malta in Libya.
“WHO has repeatedly stressed that equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic. No one is safe until everyone is safe. We are very grateful to the Government of Malta for its solidarity,” said Ms Elizabeth Hoff, WHO Representative in Libya. Libya is currently rolling out its national COVID-19 vaccination campaign. As of the end of July 2021, Libya received more than 1.3 million doses of COVD-19 vaccine from different sources. To date, over half a million people have received their first dose of the vaccine in the country.
Distributed by APO Group on behalf of WHO Regional Office for the Eastern Mediterranean.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
